New drug aimed at folate receptor shows promise for tough endometrial cancer
Disease control
Recruiting now
This phase 2 trial tests a drug called mirvetuximab soravtansine in 50 women with a specific type of endometrial cancer that has come back or won't go away. The drug targets a protein called folate receptor alpha, which is often found on these cancer cells. Researchers want to se…
Phase: PHASE2 • Sponsor: Alessandro Santin • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC